COMPARISON OF LEVOFLOXACIN BASED VERSUS CLARITHROMYCIN BASED TRIPLE REGIMEN THERAPY FOR IN THE ERADICATION OF HELICOBACTER PYLORI
DOI:
https://doi.org/10.71000/cz495x34Keywords:
Amoxicillin, Clarithromycin, , Helicobacter pylori, Levofloxacin, , Omeprazole, Triple therapy, Urea breath testAbstract
Background: Helicobacter pylori is a globally prevalent gastric pathogen implicated in chronic gastritis, peptic ulcer disease, and gastric malignancies. Rising resistance to commonly used antibiotics, particularly clarithromycin, has led to declining eradication success rates with conventional therapies. Levofloxacin, a fluoroquinolone antibiotic, has emerged as a potential alternative in triple therapy regimens. Evaluating the comparative effectiveness of these treatment options in different populations is essential to guide empirical clinical practice and adapt to regional antibiotic resistance patterns.
Objective: To compare the success of levofloxacin-based versus clarithromycin-based triple regimen therapy in the eradication of Helicobacter pylori infection.
Methods: This randomized controlled trial was conducted at the Department of Gastroenterology, Sheikh Zayed Medical Complex, Lahore, from April 2 to October 2, 2020. A total of 120 patients, aged 16 to 75 years and diagnosed with H. pylori via ^13C urea breath test, were enrolled and randomly allocated into two equal groups. Group A received omeprazole 40 mg, amoxicillin 1 g, and levofloxacin 250 mg twice daily for 14 days. Group B received omeprazole 40 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for the same duration. After 28 days of treatment completion, H. pylori status was reassessed using the ^13C urea breath test. Eradication success was defined by a negative result.
Results: The mean age of participants was 44.58 ± 15.16 years, with 88 patients (73.3%) being male. Successful eradication was achieved in 49 patients (81.7%) in the levofloxacin group compared to 39 patients (65.0%) in the clarithromycin group. The difference was statistically significant (p = 0.039).
Conclusion: Levofloxacin-based triple therapy demonstrated significantly higher eradication rates than clarithromycin-based therapy, supporting its use as a more effective regimen for the treatment of Helicobacter pylori infection in adult populations.
References
Schubert JP, Gehlert J, Rayner CK, Roberts-Thomson IC, Costello S, Mangoni AA, et al. Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2021;36(6):1450-6.
Zeng S, Kong Q, Wu X, Duan M, Nan X, Yang X, et al. Antibiotic resistance of Helicobacter pylori in Mainland China: A focus on geographic differences through systematic review and meta-analysis. Int J Antimicrob Agents. 2024;64(5):107325.
Ayaş M, Gürol Y. Antibiotic Resistance of Helicobacter pylori in Turkey: A Systematic Review and Meta-Analysis. Microb Drug Resist. 2023;29(3):96-103.
Kotilea K, Iliadis E, Nguyen J, Salame A, Mahler T, Miendje Deyi VY, et al. Antibiotic resistance, heteroresistance, and eradication success of Helicobacter pylori infection in children. Helicobacter. 2023;28(5):e13006.
Ashkar Daw M, Azrad M, Peretz A. Associations between biofilm formation and virulence factors among clinical Helicobacter pylori isolates. Microb Pathog. 2024;196:106977.
Wang L, Zhang J, Hu M, Pang X. Comparison of Drug Resistance of Helicobacter pylori Between Children and Adults in Jilin, China. Turk J Gastroenterol. 2021;32(12):1012-8.
Min BJ, Seo ME, Bae JH, Kim JW, Kim JH. Development and validation of next-generation sequencing panel for personalized Helicobacter pylori eradication treatment targeting multiple species. Front Cell Infect Microbiol. 2024;14:1379790.
Han Z, Li Y, Kong Q, Liu J, Wang J, Wan M, et al. Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis. Helicobacter. 2022;27(6):e12930.
Islam JM, Yano Y, Okamoto A, Matsuda R, Shiraishi M, Hashimoto Y, et al. Evidence of Helicobacter pylori heterogeneity in human stomachs by susceptibility testing and characterization of mutations in drug-resistant isolates. Sci Rep. 2024;14(1):12066.
Ho JJC, Navarro M, Sawyer K, Elfanagely Y, Moss SF. Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2022;117(8):1221-30.
Kamal A, Ghazy RM, Sherief D, Ismail A, Ellakany WI. Helicobacter pylori eradication rates using clarithromycin and levofloxacin-based regimens in patients with previous COVID-19 treatment: a randomized clinical trial. BMC Infect Dis. 2023;23(1):36.
Nestegard O, Moayeri B, Halvorsen FA, Tønnesen T, Sørbye SW, Paulssen E, et al. Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure. PLoS One. 2022;17(4):e0265322.
Ang TL, Ang D. Helicobacter pylori Treatment Strategies in Singapore. Gut Liver. 2021;15(1):13-8.
Guevara B, Cogdill AG. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Dig Dis Sci. 2020;65(7):1917-31.
Zeng J, Xie C, Zhang L, Liu X, Chan MTV, Wu WKK, et al. Host Cell Antimicrobial Responses against Helicobacter pylori Infection: From Biological Aspects to Therapeutic Strategies. Int J Mol Sci. 2022;23(18).
Örsten S, Yılmaz E, Akyön Y. Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains. Turk J Gastroenterol. 2023;34(4):427-32.
Hong TC, El-Omar EM, Kuo YT, Wu JY, Chen MJ, Chen CC, et al. Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2024;9(1):56-67.
Han X, Yu X, Gao X, Wang X, Tay CY, Wei X, et al. Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy. Helicobacter. 2023;28(4):e12985.
Yu J, Lv YM, Yang P, Jiang YZ, Qin XR, Wang XY. Safety and effectiveness of vonoprazan-based rescue therapy for Helicobacter pylori infection. World J Gastroenterol. 2023;29(20):3133-44.
Losurdo G, D'Abramo FS, Piazzolla M, Rima R, Continisio A, Pricci M, et al. Second-line Therapy for Helicobacter Pylori Eradication: State of the Art. Mini Rev Med Chem. 2022;22(19):2430-7.
Zhou Y, Zhong Z, Hu S, Wang J, Deng Y, Li X, et al. A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China. Antimicrob Agents Chemother. 2022;66(6):e0218821.
Waqar F, Noor M, Haider E, Farhat K, Ali S, Fatime Gilani SF. Therapeutic efficacy and drug safety comparison of one-week Vonoprazan triple therapy with two-weeks Esomeprazole triple therapy in Helicobacter pylori infection: Findings from a single-centre randomized clinical trial in population of Pakistan. J Pak Med Assoc. 2024;74(3):432-5.
Tong Y, Dang R, Yin Y, Men C, Xi R. A whole genome sequencing-based assay to investigate antibiotic susceptibility and strain lineage of Helicobacter pylori. Microb Pathog. 2024;197:107069.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Fasih Ur Rehman, Hira Fatima, Muhammad Adil Zaka Khan (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
